Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. [electronic resource]
Producer: 20191007Description: 436-445 p. digitalISSN:- 1528-0020
- Adenine -- analogs & derivatives
- Adult
- Agammaglobulinaemia Tyrosine Kinase -- antagonists & inhibitors
- Aged
- Antineoplastic Agents -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Central Nervous System Neoplasms -- drug therapy
- Circulating Tumor DNA -- genetics
- Female
- Humans
- Lymphoma -- drug therapy
- Methotrexate -- adverse effects
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Piperidines
- Protein Kinase Inhibitors -- adverse effects
- Pyrazoles -- adverse effects
- Pyrimidines -- adverse effects
- Rituximab -- adverse effects
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.